非布司他对痛风伴高尿酸血症患者的治疗效果及预后观察

Therapeutic effect and prognosis of febuxostat on gout patients with hyperuricemia

目的 探究非布司他对痛风高尿酸血症患者的治疗效果。方法 48例痛风伴高尿酸血症患者,按照治疗方法的不同分为观察组和对照组,各24例。对照组选择别嘌醇进行治疗,观察组选择非布司他进行治疗。对比两组患者治疗前后的血尿酸水平、治疗效果以及不良反应发生情况。结果 治疗4、8周后,观察组患者血尿酸水平分别为(402.37±52.38)、(380.24±47.75)μmol/L,均低于对照组的(462.22±48.33)、(427.23±45.67)μmol/L,差异具有统计学意义(P<0.05)。观察组患者临床总有效率95.83%显著高于对照组的75.00%,差异具有统计学意义(P<0.05)。观察组患者不良反应发生率8.33%显著低于对照组的33.33%,差异具有统计学意义(P<0.05)。结论 针对痛风伴高尿酸血症患者选择非布司他治疗,显著疗效,对尿酸的抑制效果理想,提升临床治疗效果,值得临床推广和借鉴。

Objective To investigate the therapeutic effect of febuxostat on gout patients with hyperuricemia. Methods A total of 48 patients with gout and hyperuricemia were divided into observation group and control group according to different treatment methods, with 24 cases in each group. The control group was treated with allopurinol, and the observation group was treated with febuxostat. The serum uric acid level before and after treatment, therapeutic effect and occurrence of adverse reactions were compared between the two groups.Results After 4 and 8 weeks of treatment, the serum uric acid levels in the observation group were(402.37±52.38)and(380.24±47.75) μmol/L, which were lower than(462.22±48.33) and(427.23±45.67) μmol/L in the control group, and the difference was statistically significant(P<0.05). The total clinical effective rate in the observation group was 95.83%, which was significantly higher than 75.00% in the control group, and the difference was statistically significant(P<0.05). The incidence of adverse reactions in the observation group was 8.33%, which was significantly lower than 33.33% in the control group, and the difference was statistically significant(P<0.05).Conclusion Febuxostat is effective in the treatment of gout with hyperuricemia, and it has an ideal inhibitory effect on uric acid, and can improve the clinical treatment effect, which is worthy of clinical promotion and reference.